• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Do Uterine Cancer Death Rates Vary Based on Tumor Characteristics According to Race and Ethnicity?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Rates of uterine cancer have been increasing, particularly aggressive, nonendometrioid subtypes of uterine cancer
    • Rates of uterine cancer are also disproportionally higher among non-Hispanic Black women
  • Clarke et al. (JAMA Oncology, 2022) estimated histologic subtype- and stage-specific uterine cancer mortality rates by race and ethnicity, corrected for hysterectomy

METHODS:

  • Cohort study
  • Population
    • Women in the SEER database with uterine cancer diagnosed between 2000 and 2017
    • <40 years excluded due to low number of deaths in this age cohort
  • Exposures
    • Tumor histologic subtype
    • Cancer stage at diagnosis
    • Race and ethnicity
  • Study design
    • Hysterectomy correction was based on hysterectomy prevalence data from the Behavioral Risk Factor Surveillance System
      • For the hysterectomy-corrected rates, proportion of women with a hysterectomy were from the denominator
    • The primary outcomes were calculated as corrected and uncorrected rates, and were age-adjusted to the 2000 US standard population
    • Annual percent changes in rates were calculated using log-linear regression
  • Primary outcomes
    • Rates of uterine cancer diagnoses
    • Rates of uterine cancer deaths

RESULTS:

  • 208,587 women diagnosed with uterine cancer during study period
    • Asian: 7.7%
    • Black: 9.7%
    • Hispanic: 11.1%
    • White: 71.5%
  • Uterine cancer deaths during study period: 16,797
    • Hysterectomy-corrected mortality rate: 15.7 per 100,000 person-years
  • Hysterectomy-corrected rates were highest among Black women
    • Overall
    • By histologic subtype
    • By stage at diagnosis
  • Among all women, cancer mortality rates increased significantly every year
    • Uterine corpus cancer
      • By 1.8% (95% CI, 1.5 to 2.9%) per year
    • Nonendometrioid carcinomas
      • By 2.7% (95% CI, 1.8 to 3.6%) per year
  • Increases in cancer mortality rates occurred in women of all race/ethnicities
    • Asian women
      • By 3.4% (95% CI, 0.3 to 6.6%) per year
    • Black women
      • By 3.5% (95% CI, 2.2 to 4.9%) per year
    • Hispanic women
      • By 6.7% (95% CI, 1.9 to 11.8%) per year
    • White women
      • By 1.5% (95% CI, 0.6 to 2.4%) per year
  • Endometrioid carcinoma mortality rates remained stable

CONCLUSION:

  • From 2000 to 2017 there was a significant increase in nonendometrioid uterine carcinoma mortality rates among US women
  • Disparities in uterine corpus cancer rates among non-Hispanic Black women don’t appear to be explained by subtype distribution and stage at diagnosis
  • While incident uterine cancer cases among Black women was <10%, mortality was nearly 18%
  • The authors state

Increasing nonendometrioid carcinoma mortality rates align with recent incidence trends of these aggressive subtypes, which have been increasing over the past 2 decades

In contrast, mortality rates for endometrioid carcinomas have not changed substantially over time among all racial and ethnic groups

Learn More – Primary Sources:

Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Uterine and Ovarian Cancer Trends Over the Past Two Decades: How Have Mortality Rates Changed Across Race and Ethnicity?
How Common is Unexpected Uterine Cancer at Hysterectomy?
What is the Proportion of Cancer Attributable to Obesity in the U.S.?
Does Assisted Reproduction Increase Risk of Breast, Ovarian, Uterine Cancer?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site